Abstract
Biotechnology Law ReportVol. 29, No. 1 REGULATORY AFFAIRS—PHARMACEUTICALTransparency Initiative Launched; FDA Describes What It Does; Genzyme Resumes Product Shipments; FDA to Take Another Look at Epo; New Type of Biologic Approved for Rheumatoid Arthritis; More Information to Be Available on Tysabri Complication; Nanotechnology Safety Act Introduced in Congress; Problems with GINA?; Anti-Bioterror Efforts Found Wanting; Teva Files for Biosimilar Filgrastim; When Can a Company Not Be Fined for Off-Label Promotion?; FDA Should Add Safety Symbol to Web Sites for Prescription Drugs; How Is Human DNA Used in Animals?Published Online:22 Apr 2010https://doi.org/10.1089/blr.2010.9986AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetails Volume 29Issue 1Feb 2010 Information© 2010 Mary Ann Liebert, Inc.To cite this article:Transparency Initiative Launched; FDA Describes What It Does; Genzyme Resumes Product Shipments; FDA to Take Another Look at Epo; New Type of Biologic Approved for Rheumatoid Arthritis; More Information to Be Available on Tysabri Complication; Nanotechnology Safety Act Introduced in Congress; Problems with GINA?; Anti-Bioterror Efforts Found Wanting; Teva Files for Biosimilar Filgrastim; When Can a Company Not Be Fined for Off-Label Promotion?; FDA Should Add Safety Symbol to Web Sites for Prescription Drugs; How Is Human DNA Used in Animals?.Biotechnology Law Report.Feb 2010.33-37.http://doi.org/10.1089/blr.2010.9986Published in Volume: 29 Issue 1: April 22, 2010PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
